Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Extramedullary multiple myeloma (EMD) is an aggressive subentity of multiple myeloma (MM) with poor prognosis. As more innovative therapeutic approaches are needed for the treatment of MM with EMD, we conducted this multicenter, non-randomized phase II trial of daratumumab in combination with dexame...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Ja Min, Min, Chang-Ki, Kim, Kihyun, Bang, Soo-Mee, Lee, Je-Jung, Kim, Jin Seok, Yoon, Sung-Soo, Koh, Youngil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590218/
https://www.ncbi.nlm.nih.gov/pubmed/36274163
http://dx.doi.org/10.1186/s13045-022-01374-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590218/
https://www.ncbi.nlm.nih.gov/pubmed/36274163
http://dx.doi.org/10.1186/s13045-022-01374-5

Ejemplares similares